Intercept Pharmaceuticals (ICPT) Strikes a Deal with Advanz for Ocaliva Implying a $20/sh Takeout Price - Raymond James
Tweet Send to a Friend
Raymond James analyst Steven Seedhouse reiterated an Outperform rating and $44.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
